Gene: KCNIP4

80333
CALP|KCHIP4
potassium voltage-gated channel interacting protein 4
protein-coding
4p15.31-p15.2
Ensembl:ENSG00000185774 MIM:608182 Vega:OTTHUMG00000128557 UniprotKB:Q6PIL6
NG_052969.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.997e-1 (AD)  7.546e-2 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg04177287chr4:21857313KCNIP4Promoter9.877e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RBFOX10.974
GABRG20.974
FGF120.973
NMNAT20.966
NSF0.966
RGS70.965
SNAP910.964
NAPB0.964
PAK30.964
MAP7D20.963

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.527
HEY2-0.523
CNN2-0.512
RAI14-0.502
MYL3-0.496
REST-0.49
FZD10-0.49
RUNX3-0.489
SYDE1-0.485
MAGEA12-0.48

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCNIP4 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCNIP4 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCNIP4 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCNIP4 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCNIP4 mRNA"25510870
C0235142,6-dinitrotoluene"2,6-dinitrotoluene results in decreased expression of KCNIP4 mRNA"20406850
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNIP4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNIP4 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of KCNIP4 gene27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of KCNIP4 mRNA24449571
C006632arsenic trioxidearsenic trioxide results in decreased expression of KCNIP4 mRNA26705709
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of KCNIP4 mRNA22316170
C006780bisphenol A[bisphenol A co-treated with Testosterone] results in decreased expression of KCNIP4 mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of KCNIP4 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of KCNIP4 gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of KCNIP4 mRNA26079696
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of KCNIP4 mRNA20971185
D019327Copper SulfateCopper Sulfate results in decreased expression of KCNIP4 mRNA19549813
D003471CuprizoneCuprizone results in decreased expression of KCNIP4 mRNA26577399
D016572CyclosporineCyclosporine results in decreased methylation of KCNIP4 promoter27989131
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of KCNIP4 mRNA23914054
C014347decitabinedecitabine results in increased expression of KCNIP4 mRNA21856257
D002945CisplatinCisplatin results in decreased expression of KCNIP4 mRNA27392435
C039281furanfuran results in increased methylation of KCNIP4 gene22079235
C412815GW 4064GW 4064 results in increased expression of KCNIP4 mRNA26655953
C544151jinfukangjinfukang results in decreased expression of KCNIP4 mRNA27392435
D007854LeadLead affects the expression of KCNIP4 mRNA28903495
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of KCNIP4 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of KCNIP4 mRNA"25554681
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of KCNIP4 mRNA20971185
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCNIP4 mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KCNIP4 mRNA"27188386
D011374ProgesteroneProgesterone results in increased expression of KCNIP4 mRNA22238285
D011441PropylthiouracilPropylthiouracil results in decreased expression of KCNIP4 mRNA24780913
C502851quinocetonequinocetone results in increased expression of KCNIP4 mRNA27046791
C017947sodium arsenitesodium arsenite affects the methylation of KCNIP4 gene28589171
D012999SomanSoman results in decreased expression of KCNIP4 mRNA19281266
D013739TestosteroneTestosterone results in increased expression of KCNIP4 mRNA19693291
D013739Testosterone[bisphenol A co-treated with Testosterone] results in decreased expression of KCNIP4 mRNA26496021
D014028Tobacco Smoke PollutionTobacco Smoke Pollution results in increased expression of KCNIP4 mRNA19969065
D014212TretinoinTretinoin results in increased expression of KCNIP4 mRNA21934132
D014635Valproic AcidValproic Acid results in decreased expression of KCNIP4 mRNA23179753|2718838
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of KCNIP4 gene25560391
C029297vinylidene chloridevinylidene chloride results in increased expression of KCNIP4 mRNA26682919
C088658zoledronic acidzoledronic acid results in decreased expression of KCNIP4 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005244voltage-gated ion channel activity-IEA-  
GO:0005267potassium channel activity-IEA-  
GO:0005509calcium ion binding-IDA11847232  
GO:0005515protein binding-IPI26871637  
GO:0015459potassium channel regulator activity-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0071805potassium ion transmembrane transport-IEA-  
GO:0072659protein localization to plasma membrane-ISS-  
GO:1901379regulation of potassium ion transmembrane transport-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IDA11847232  
GO:0005783endoplasmic reticulum-IEA-  
GO:0005829cytosol-ISS-  
GO:0005886plasma membrane-IDA11847232  
GO:0005886plasma membrane-ISS-  
GO:0005886plasma membrane-TAS-  
GO:0008076voltage-gated potassium channel complex-ISS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-397014Muscle contractionTAS
R-HSA-5576891Cardiac conductionTAS
R-HSA-5576894Phase 1 - inactivation of fast Na+ channelsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24419231Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS data. (2014 May)Tang HCarcinogenesis
25644374Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancer. (2015 Mar)Poirier JGGenet Epidemiol